Bioxytran (BIXT) Asset Utilization Ratio (2011 - 2018)
Bioxytran (BIXT) posted Asset Utilization Ratio of 0.26 for Q2 2018, down 54.68% sequentially from 0.57 in Q1 2018, and down 96.82% YoY from 8.12 in Q2 2017.
Bioxytran (BIXT) Asset Utilization Ratio (2011 - 2018) Analysis & Trends
Bioxytran has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.26 in Q2 2018.
- Quarterly Asset Utilization Ratio fell 96.82% year-over-year to 0.26 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 0.26 (down 96.82% YoY) and the FY2017 annual result came in at 7.38, up 60.91% from the prior year.
- Asset Utilization Ratio eased to 0.26 in Q2 2018 per BIXT's latest filing, from 0.57 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 8.12 in Q2 2017 and troughed at 35.27 in Q1 2016.
- A 5-year average of 4.59 and a median of 1.59 in 2014 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2016 and 2017: Asset Utilization Ratio slumped 2966.05% in 2016, then jumped 123.15% in 2017.
- Over 5 years, Asset Utilization Ratio stood at 1.64 in 2014, then tumbled by 1572.66% to 24.08 in 2015, then jumped by 115.34% to 3.69 in 2016, then soared by 34.62% to 4.97 in 2017, then tumbled by 94.81% to 0.26 in 2018.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.26, 0.57, and 4.97 for Q2 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 0.26 |
| Mar 31, 2018 | 0.57 |
| Dec 31, 2017 | 4.97 |
| Sep 30, 2017 | 4.42 |
| Jun 30, 2017 | 8.12 |
| Mar 31, 2017 | 5.50 |
| Dec 31, 2016 | 3.69 |
| Sep 30, 2016 | -27.20 |
| Jun 30, 2016 | -35.09 |
| Mar 31, 2016 | -35.27 |
| Dec 31, 2015 | -24.08 |
| Sep 30, 2015 | 2.04 |
| Jun 30, 2015 | 1.40 |
| Mar 31, 2015 | 1.23 |
| Dec 31, 2014 | 1.64 |
| Sep 30, 2014 | 1.85 |
| Jun 30, 2014 | 1.54 |
| Mar 31, 2014 | 1.72 |
| Dec 31, 2013 | 1.67 |
| Sep 30, 2013 | 1.31 |